In conclusion, compared to the thermal or mechanical destructive impact of HIFU exposure that results in APC-presenting and macrophage-recruiting immunological changes, permeability-enhancing MB-FUS exposure presents a new opportunity to facilitate alterations in a tolerogenic tumor microenvironment, possibly serving as an independent therapeutic route or an effective adjuvant for current first-line cancer treatment. The gene discussed is APC; the disease is neoplasm.